Drug insight: The role of albumin in the management of chronic liver disease

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 4, Issue 1, 2007, Pages 43-51

  Wong, Florence ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Albumin; Ascites; Bacterial peritonitis; Cirrhosis; Hepatorenal syndrome; Spontaneous

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMMONIA; CEFOTAXIME; CREATININE; DEXTRAN 40; DEXTRAN 70; DIURETIC AGENT; FUROSEMIDE; GELATIN SUCCINATE; HETASTARCH; HUMAN ALBUMIN; POLYGELINE; SODIUM; TERLIPRESSIN; VASOCONSTRICTOR AGENT; VASOPRESSIN DERIVATIVE;

ADJUVANT THERAPY; ALBUMIN DIALYSIS; AMMONIA BLOOD LEVEL; ANTIOXIDANT ACTIVITY; ASCITES; BACTERIAL PERITONITIS; CHRONIC LIVER DISEASE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG INDICATION; DRUG INFUSION; DRUG MECHANISM; HEMODIALYSIS; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; HYPONATREMIA; KIDNEY FAILURE; LIGAND BINDING; LIVER CIRRHOSIS; META ANALYSIS; OSMOTIC PRESSURE; PARACENTESIS; PRIORITY JOURNAL; REVIEW; SODIUM RESTRICTION; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW;

ALBUMINS; BACTERIAL INFECTIONS; CHRONIC DISEASE; HEPATORENAL SYNDROME; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES; PERITONITIS;

EID: 33846074784     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep0680     Document Type: Review

References (69)

1. Evans TW (2002) Review article: Albumin as a drug - biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther 16 (Suppl 5): 6-11
2. Halliwell B (1988) Albumin, an important extracellular antioxidant. Biochem Pharmacol 37: 569-571
3. 131I-albumin catabolism and distribution in normal young male adults. J Clin Invest 41: 1312-1333
4. Peters T Jr (1997) Serum albumin. Adv Protein Chem 45: 153-203
5. Arroyo V and Colmenero J (2003) Use of albumin in the management of patients with decompensated cirrhosis. An independent verdict. Dig Liver Dis 35: 668-672
6. Nguyen MK and Kurtz I (2006) Quantitative Interrelationship between Gibbs-Donnan equilibrium, osmolality of body fluid compartments, and plasma water sodium concentration. J Appl Physiol 100: 1293-1300
7. Fasano M et al. (2005) The extraordinary ligand binding properties of human serum albumin. IUBMB Life 57: 787-796
8. Ghuman J et al. (2005) Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol 353: 38-52
9. Scharfstein JS et al. (1994) In vivo transfer of nitric oxide between a plasma protein-bound reservoir and low molecular weight thiols. J Clin Invest 94: 1432-1439
10. Greco AV et al. (2000) Subclinical hepatic encephalopathy: Role of tryptophan binding to albumin and the competition with indole-3-acetic acid. J Investig Med. 48: 274-280
11. Kouoh F et al. (1999) Antioxidant properties of albumin: Effect on oxidative metabolism of human neutrophil granulocytes. Farmaco 54: 695-699
12. Quinlan GJ et al. (2004) Albumin influences total plasma antioxidant capacity favorably in patients with acute lung injury. Crit Care Med 32: 755-759
13. Kragh-Hansen U et al. (2002) Practical aspects of the ligand binding and enzymatic properties of human serum albumin. Biol Pharm Bull 25: 695-704
14. Quinlan GJ et al. (2005) Albumin: Biochemical properties and therapeutic potentials. Hepatology 42: 1211-1219
15. Lang J D Jr et al. (2004) Albumin and hydroxyethyl starch modulate oxidative inflammatory injury to vascular endothelium. Anesthesiology 100: 51-58
16. Ramirez-Vick J and Vargas FF (1993) Albumin modulation of paracellular permeability of pig vena caval endothelium shows specificity for pig albumin. Am J Physiol Heart Circ Physiol 264: H1382-H1387
17. Margarson MP and Soni NC (2002) Effects of albumin supplementation on microvascular permeability in septic patients. J Appl Physiol 92: 2139-2145
18. Mendez CM et al. (2005) Albumin therapy in clinical practice. Nutr Clin Pract 20: 314-320
19. Margarson MP and Soni NC (2004) Albumin, where are we now? Curr Anaesth Crit Care 15: 61-68
20. Cochrane Injuries Group Albumin Reviewers (1998) Human albumin administration in critically ill patients: Systematic review of randomized controlled trials. BMJ 317: 235-240
21. The SAFE Study Investigators (2004) A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 350: 2247-2256
22. Laub R and Strengers P (2002) Parvoviruses and blood products. Pathol Biol 50: 339-348
23. Wilkes MM and Navickis RJ (2001) Patient survival after human albumin administration: A meta-analysis of randomized controlled trials. Ann Intern Med 135: 149-164
24. Finfer SR et al. (2004) The SAFE Study: A landmark trial of the safety of albumin in intensive care. Med J Aust 181: 237-238
25. Schrier RW et al. (1988) Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8: 1151-1157
26. Borzio M et al. (2001) Bacterial infection in patients with advanced cirrhosis: A multicentre prospective study. Dig Liver Dis 33: 41-48
27. Moore KP et al. (2003) The management of ascites-report on the consensus conference of the International Ascites Club. Hepatology 38: 258-266
28. Burroughs AK (2003) Is the use of albumin of value in cirrhosis? The case not so in favour, or is there an alternative? Dig Liver Dis 35: 664-667
29. Laffi G et al. (2003) Is the use of albumin of value in the treatment of ascites in cirrhosis? The case in favour. Dig Liver Dis 35: 660-663
30. Chalasani N et al. (2001) Effects of albumin/furosemide mixtures on responses to furosemide in hypoalbuminemic patients. J Am Soc Nephrol 12: 1010-1016
31. Gines P et al. (1988) Randomized comparative study of therapeutic parcentesis with and without intravenous albumin in cirrhosis. Gastroenterology 94: 1493-1502
32. Ginès A et al. (1996) Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 111: 1002-1010
33. Altman C et al. (1998) Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. Eur J Gastroenterol Hepatol 10: 5-10
34. Planas R et al. (1990) Dextran-70 versus albumin as plasma expanders in cirrhotic patients with ascites treated with total paracentesis. Results of a randomized study. Gastroenterology 99: 1736-1744
35. Salerno F et al. (1991) Randomized comparative study of hemaccel vs albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology 13: 707-713
36. Fassio E et al. (1992) Paracentesis with dextran 70 vs paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. J Hepatol 14: 310-316
37. Moreau R et al. (2006) Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid. Liver Int 26: 46-54
38. Garcia-Compean D et al. (2002) Treatment of cirrhotic tense ascites with dextran-40 versus albumin associated with large volume paracentesis: A randomized controlled trial. Ann Hepatol 1: 29-35
39. Sola-Vera J et al. (2003) Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 37: 1147-1153
40. Moreau R et al. (2002) Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: A randomised pilot study. Gut 50: 90-94
41. Ruiz-del-Arbol L et al. (1997) Paracentesis-induced circulatory dysfunction: Mechanism and the effect on hepatic hemodynamics in cirrhosis. Gastroenterology 113: 579-586
42. Peltekian K et al. (1997) The effect of large volume paracentesis on total central blood volume, systemic and renal hemodynamics and renal sodium handling in cirrhosis. Am J Gastroenterol 92: 394-399
43. Vermeulen LC Jr et al. (1995) A paradigm for consensus. The University Hospital Consortium guidelines for the use of albumin, nonprotein colloid, and crystalloid solutions. Arch Intern Med 155: 373-379
44. Runyon BA (2004) Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Management of adult patients with ascites due to cirrhosis. Hepatology 39: 841-856
45. Follo A et al. (1994) Renal impairment after spontaneous bacterial peritonitis in cirrhosis: Incidence, clinical course, predictive factors and prognosis. Hepatology 20: 1495-1501
46. Hoefs JC et al. (1982) Spontaneous bacterial peritonitis. Hepatology 2: 399-407
47. Sort P et al. (1999) Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 341: 403-409
48. Patch D and Burroughs A (1999) Intravenous albumin in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 341: 1773-1774
49. Mogyorosi A and Schubert ML (2000) Intravenous albumin reduces mortality in patients with spontaneous bacterial peritonitis. Gastroenterology 118: 231-233
50. Brand RE (1999) Intravenous albumin in patients with cirrhosis and spontaneous bacterial peritonitis: Is it worth the cost? Am J Gastroenterol 94: 3404
51. Runyon BA (1999) Albumin infusion for spontaneous bacterial peritonitis. Lancet 354: 1838-1839
52. Fernández J et al. (2005) Randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 42: 627-634
53. Wong F (2005) Volume expanders for spontaneous bacterial peritonitis: are we comparing oranges with oranges? Hepatology 42: 533-535
54. Gines P et al. (2003) Hepatorenal syndrome. Lancet 362: 1819-1827
55. Moreau R et al. (2002) Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: A retrospective multicenter study. Gastroenterology 122: 923-930
56. Guevara M et al. (1998) Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 27: 35-41
57. Duvoux C et al (2002) Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: A pilot study. Hepatology 36: 374-380
58. Wong F et al. (2004) The use of midodrine, octreotide and transjugular intrahepatic portosystemic stent shunt in the treatment of cirrhotic patients with ascites and renal dysfunction including hepatorenal syndrome. Hepatology 40: 55-64
59. Ortega R et al. (2002) Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study. Hepatology 36: 941-948
60. McCormick PA et al. (1990) Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites. Gut 31: 204-207
61. Jalan R and Kapoor D (2004) Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid. Clin Sci 106: 467-474
62. Butterworth RF (2003) Role of circulating neuratoxins in the pathogenesis of hepatic encephalopathy: Potential for improvement following their removal by liver assist devices. Liver Int 23 (Suppl 3): 5-9.
63. Lumsden A et al. (1988) Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. Hepatology 8: 232-236
64. Sogni P et al. (1992) Evidence for normal nitric oxide-mediated vasodilator tone in conscious rats with cirrhosis. Hepatology 16: 980-983
65. Stange J et al. (2005) Short-term survival of patients with severe intractable hepatic encephalopathy: The role of albumin dialysis. [Abstract]. Hepatology 42 (Suppl 1): 286A
66. Mitzner SR et al. (2000) Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: Results of a prospective, randomized, controlled clinical trial. Liver Transpl 6: 277-286
67. Stange J et al. (2002) The molecular adsorbents recycling system as a liver support system based on albumin dialysis: A summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers. Artif Organs 26: 103-110
68. Sen S et al. (2004) Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: A randomized controlled study. Liver Transpl 10: 1109-1119
69. Cook D (2004) Is albumin safe? N Engl J Med 350: 2294-2296